Atlas market file · Equity · United States
UroGen Pharma Ltd.URGN
- Last close
- 45.6
- Change
- -1.79%
- 96-bar range
- 16.5 – 48.03
- As of
- 6 Aug 2026
UroGen Pharma Ltd. is a pharmaceutical preparations issuer listed as URGN on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
URGN
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+222.03% over the window).
Source rail: Yahoo Finance chart API (URGN). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for URGN. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
URGN public profile
Pharmaceutical preparations issuer. UroGen Pharma Ltd. is connected to current market context, cited company sources and its retained research file.
UroGen Pharma Ltd. trades as URGN on NASDAQ. UroGen Pharma Ltd. (URGN) has a latest verified close of 45.6, down 1.79%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files URGN under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for UroGen Pharma Ltd. today
UroGen Pharma Ltd. (URGN) reported $51 million in Q1 2026 revenue, a 150% surge from the same period in 2025, driven by its Jelmyto® therapy and RTGel® technology platform. However, the company’s financials reveal a stark contrast: a $23.6 million net loss, $45.3 million cash burn from operations, and cumulative liabilities exceeding assets by $124.3 million. (source: SEC EDGAR 10-Q)
The company’s RTGel® technology, designed for intracavitary urological treatments, remains central to its narrative. Despite inventory rising to $20.9 million (a $4.5 million increase), UroGen’s ability to convert product into sustainable cash flow remains unproven. The firm’s $110 million cash reserves, offset by $39.7 million in short-term investments, buy time but don’t resolve the equity deficit. (source: SEC EDGAR 10-Q)
Recent developments include a January 2024 license deal with medac and positive Phase 3 trial results for UGN-103. Yet, with R&D expenses at $15.6 million and no dividend/buyback activity, shareholders face a binary: bet on pipeline approvals or brace for dilution. The company’s lease agreements for sales vehicles, disclosed alongside losses, highlight the tension between operational ambition and financial reality. (source: SEC EDGAR 4, UroGen Pipeline)
UroGen’s stock trades on the Nasdaq, but its survival hinges on clinical progress, not market optics. The 10-Q shows no buybacks, 12% sequential revenue growth, and a $54,000 capex spend-peanuts for a biotech burning tens of millions quarterly. The real catalyst? Regulatory approvals for UGN-103 and UGN-102, which could justify the $253 million asset base or accelerate its erosion. (source: SEC EDGAR 10-Q, SEC EDGAR 144)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
URGN technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on URGN
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep URGN research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
URGN FAQ
What is UroGen Pharma Ltd. (URGN)?UroGen Pharma Ltd. (URGN) has a latest verified close of 45.6, down 1.79%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
UroGen Pharma Ltd. (URGN) has a latest verified close of 45.6, down 1.79%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for URGN?UroGen Pharma Ltd. (URGN) has a latest verified close of 45.6, down 1.79%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
UroGen Pharma Ltd. (URGN) has a latest verified close of 45.6, down 1.79%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files URGN under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the URGN page updated?The URGN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The URGN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for URGN?The URGN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:URGN. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The URGN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:URGN. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on URGN?Yes. The workstation can open URGN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open URGN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this URGN page investment advice?No. The URGN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The URGN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →